齐鲁晚报.齐鲁壹点陈甜田通讯员吴萌萌 近日，山东省卫生健康委员会发布2025年度适宜卫生技术推广项目名单，由滨州市人民医院呼吸与危重症医学科主持申报的"呼吸康复适宜技术在慢性呼 吸系统疾病中的应用"项目，经多轮严格评审，成功入选省级推广项目。这标志着滨州市人民医院呼吸康复技术正式成为省级"样板"，未来将向全省基层 医疗机构推广。 据了解，该项目由呼吸与危重症医学科护士长吴萌萌主持。 技术简介：呼吸康复，重塑呼吸健康 呼吸康复是以呼吸生理、运动医学和康复医学为基础，通过科学评估与个性化干预，改善患者呼吸功能、运动耐力和生活质量的非药物治疗体系。 核心技术包括： 呼吸生理重塑训练：腹式呼吸、缩唇呼吸、呼吸肌力量训练等； 多模态干预技术：体位引流、有氧运动、中西医融合康复方案； 智能设备支持：自适应呼吸训练器、远程评估云平台等； 该技术适用于慢性阻塞性肺疾病、哮喘、间质性肺病、围手术期患者及老年呼吸功能减退人群，能显著提升肺功能、减少急性加重、缩短住院时间，具有 良好的安全性、经济性与推广性。 学科支撑：省级重点专科，实力保障 滨州市人民医院呼吸与危重症医学科是山东省公共卫生重点专科、国家呼吸康复规范化建设达标单位 ...

Investment Rating - The report maintains a "Buy" rating for the medical services industry, suggesting a positive outlook for the sector in the next 6-12 months [9][63]. Core Insights - The medical services sector has shown resilience, with a recent performance boost attributed to the seasonal increase in flu cases, despite ongoing cost control pressures from medical insurance [9][63]. - The report highlights the significance of the recent government initiative to promote provincial-level medical insurance coordination, which is expected to enhance the efficiency of fund utilization and improve the overall healthcare system [5][6][61]. - The medical services sector's current Price-to-Earnings (PE) ratio is 31.62, with a Price-to-Book (PB) ratio of 3.18, indicating a slight increase from the previous week [4][29]. Summary by Sections Industry Performance - The pharmaceutical and biological sector experienced a decline of 2.67% this week, ranking 17th among 31 primary industries [2][11]. - The medical services sub-sector reported a slight increase of 1.42%, closing at 6237.83 points [22][23]. Company Performance - Top-performing companies in the medical services sector include ST Zhongzhu (+16.3%), Baihua Pharmaceutical (+11.6%), and Lanwei Medical (+10.6%) [3][27]. - Underperforming companies include Aier Eye Hospital (-1.6%) and WuXi AppTec (-0.7%) [3][27]. Valuation Metrics - The medical services sector's PE ratio has increased by 0.40 from the previous week, while the PB ratio has risen by 0.04 [4][29]. - The maximum and minimum PE ratios over the past year were 41.13 and 28.46, respectively, indicating a relatively stable valuation range [4][29]. Government Policy Impact - The recent government meeting emphasized the importance of provincial-level medical insurance coordination, which aims to balance fund distribution across regions and enhance the overall healthcare system [5][6][61]. - The report identifies structural opportunities for the pharmaceutical industry, particularly in innovative drugs, medical devices, and healthcare information technology, as a result of the new insurance policies [6][62]. Investment Recommendations - The report suggests focusing on high-growth areas such as pharmaceutical outsourcing services and companies with improving profit margins, including WuXi AppTec and Aier Eye Hospital [9][63].

Core Insights - The article highlights the initiative of the Zhongxiang People's Hospital to enhance healthcare services by integrating provincial-level expert resources into local communities, thereby improving accessibility and quality of care for residents [1][2][3] Group 1: Expert Integration and Service Expansion - The Zhongxiang People's Hospital has established a dual-service model that combines inviting top provincial experts and sending local medical staff to rural areas, significantly improving county-level healthcare capabilities [1] - As of now, 31 provincial-level expert studios have been set up at Zhongxiang People's Hospital, covering 23 disciplines including internal medicine, surgery, gynecology, pediatrics, and traditional Chinese medicine [1] Group 2: Community Engagement and Outreach - The hospital has developed specialized clinics such as pediatric asthma, allergy centers, and mental health centers, which have notably enhanced diagnostic and treatment capabilities [2] - Medical teams regularly conduct outreach in rural areas, providing care and education to local residents, thereby fostering a better understanding of health issues among the community [2] Group 3: Technological Advancements in Healthcare - The establishment of a remote medical platform has allowed the hospital to conduct over 15,000 remote electrocardiogram consultations, 6,400 remote imaging consultations, and 380 pathology consultations, enabling patients to receive expert-level care without traveling [2] Group 4: Future Directions - The Zhongxiang People's Hospital aims to continue its dual approach of bringing in top experts while strengthening local medical staff, contributing to sustainable health development in the region [3]

Core Viewpoint - The integration of artificial intelligence (AI) in healthcare is being promoted to enhance service capabilities, optimize resource allocation, and meet the growing health service demands of the population [1][2][3] Group 1: AI Applications in Healthcare - AI technologies are being applied in various medical fields, including medical imaging diagnosis, clinical decision support, and chronic disease management [1] - The implementation of AI in healthcare aims to provide personalized health management suggestions and assist primary care physicians with diagnostic and treatment processes [1][2] Group 2: Implementation Guidelines - Five departments have released guidelines to promote and regulate the application of AI in healthcare, with a timeline set for 2030 to achieve comprehensive coverage of intelligent assistance in primary care [1][2] - Specific measures include promoting intelligent diagnostic services, expanding clinical decision support applications, and enhancing chronic disease management services [2] Group 3: Focus Areas - The guidelines emphasize the importance of grassroots applications, clinical diagnosis, patient services, and public health [2] - There is a focus on developing intelligent health management services, including health consultations and personalized health profiles for chronic disease management [2] Group 4: Regulatory and Safety Measures - The approach to AI in healthcare emphasizes empowerment rather than replacement, with a commitment to optimizing industry management and enhancing data security and privacy protection [3] - Plans include establishing clinical specialty data sets and AI corpus, as well as creating a public support service platform for vertical AI models in the healthcare sector [3]

Core Viewpoint - The integration of artificial intelligence (AI) in healthcare is being promoted to enhance service capabilities, optimize resource allocation, and meet the growing health service demands of the population, with a target for comprehensive implementation by 2030 [1][2]. Group 1: AI Applications in Healthcare - AI is being utilized in various medical fields, including imaging diagnosis, clinical decision support, and chronic disease management, providing personalized health management advice through tools like "digital doctors" [1]. - The implementation plan emphasizes the need for AI applications in real-world healthcare scenarios, focusing on grassroots applications, clinical diagnosis, patient services, and public health [2]. Group 2: Focus on Grassroots and Integration - The plan highlights the importance of strengthening intelligent applications in community healthcare systems, enhancing chronic disease management, and promoting health management services for vulnerable populations [2]. - There is a push for the development of new service models such as intelligent health check-ups and consultations, encouraging collaboration between medical equipment manufacturers and healthcare institutions for innovative AI solutions [2]. Group 3: Regulatory and Data Management - The initiative aims to ensure that AI enhances rather than replaces human roles in healthcare, with a focus on optimizing management and regulatory frameworks, as well as protecting data security and personal privacy [3]. - Efforts will be made to establish clinical specialty data sets and AI corpora, along with a public support service platform for vertical AI models in the healthcare sector [3].

Core Viewpoint - The integration of artificial intelligence (AI) in healthcare is being promoted to enhance service capabilities, optimize resource allocation, and meet the growing health service demands of the population by 2030 [1][2][3] Group 1: AI Applications in Healthcare - AI is being widely applied in various medical fields, including medical imaging diagnosis, clinical decision support, and chronic disease management [1] - The implementation plan emphasizes the need for AI applications to be driven by real business scenarios and to address actual needs, focusing on grassroots applications, clinical diagnosis, patient services, and public health [2] Group 2: Development Goals and Timeline - By 2030, the goal is to achieve full coverage of intelligent assistance applications in grassroots diagnosis and treatment, with secondary hospitals widely adopting AI technologies for medical imaging and clinical decision support [1][2] - A comprehensive standard and regulatory framework for "AI + healthcare" applications is expected to be established, along with the creation of leading technology innovation and talent training bases [1] Group 3: Focus Areas for Implementation - The plan highlights the importance of strengthening intelligent applications in tightly-knit county medical communities and enhancing chronic disease management services [2] - It encourages the development of new service models such as intelligent health check-ups, health consultations, and health management, while supporting collaboration between medical equipment manufacturers and healthcare institutions [2] Group 4: Regulatory and Safety Measures - The initiative aims to ensure that AI empowers rather than replaces healthcare professionals, optimizing industry management and regulatory systems while enhancing data security and personal privacy protection [3] - The establishment of clinical specialty data sets and AI corpus, along with a public support service platform for vertical AI models, is being explored to facilitate the effective implementation of AI in healthcare [3]

Core Viewpoint - The article discusses the blood purification device industry, highlighting the increasing prevalence of End-Stage Renal Disease (ESRD) and the growth potential of blood purification technologies in response to this global health challenge [18][21]. Market Overview - The global ESRD patient population is projected to grow from 91.33 million in 2019 to 148.51 million by 2030, with a CAGR of 4.2% [18][19]. - In China, the ESRD patient population is expected to increase from 3.025 million in 2019 to 6.132 million by 2030, with a CAGR of 5.8% [20][18]. Treatment Methods - Blood purification is the most widely used treatment for ESRD, offering higher survival rates compared to kidney transplantation and conservative treatment [21]. - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.069 million in 2023, with a CAGR of 9.8%, and is expected to reach 3.791 million by 2030, with a CAGR of 19.8% [21][23]. Blood Purification Technologies - The main blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most mature and widely applied [29]. - Hemodialysis effectively removes harmful substances and excess fluid from the blood, making it suitable for patients at various disease stages [29]. Market Size and Growth - The Chinese blood dialysis device market is projected to grow from CNY 11.63 billion in 2019 to CNY 51.52 billion by 2030, with a CAGR of 19.9% from 2023 to 2030 [30][28]. - The market share of blood dialysis devices in China is expected to see significant growth, with specific segments like blood dialysis machines and consumables also experiencing robust growth rates [30]. Competitive Landscape - Domestic companies are rapidly catching up with international competitors in the blood purification consumables sector, achieving nearly 50% market share in dialysis filters [31]. - The competitive landscape for blood dialysis machines is evolving, with domestic manufacturers improving their technology and performance to match imported products [37][33]. Policy and Market Dynamics - The article notes that the Chinese government has been implementing centralized procurement policies, leading to significant price reductions and accelerating the domestic replacement process in the blood purification market [36][35].

Investment Rating - The report does not explicitly provide an investment rating for the blood purification device industry Core Insights - The report highlights the increasing prevalence of End-Stage Renal Disease (ESRD) globally and in China, with the number of patients expected to rise significantly by 2030, indicating a growing market for blood purification devices [13][15] - Blood purification is identified as the most widely used treatment method for ESRD, with a higher survival rate compared to other treatments like kidney transplantation and conservative treatment [19] - The Chinese blood purification device market is projected to grow rapidly, driven by an increase in ESRD patients, improved reimbursement policies, and advancements in dialysis infrastructure [26] Market Overview - The global ESRD patient population increased from 9.13 million in 2019 to 11.14 million in 2023, with a CAGR of 5.1%, and is expected to reach 14.85 million by 2030 [13][14] - In China, the ESRD patient population grew from 3.03 million in 2019 to 4.13 million in 2023, with a CAGR of 8.1%, projected to reach 6.13 million by 2030 [15] - The number of patients receiving blood purification treatment in China rose from 736,000 in 2019 to 1.07 million in 2023, with a CAGR of 9.8%, expected to reach 3.79 million by 2030 [19][18] Treatment Methods - Blood purification methods include hemodialysis, peritoneal dialysis, blood perfusion, and blood filtration, with hemodialysis being the most common and effective method for ESRD patients [23] - Hemodialysis is noted for its effectiveness in removing toxins and excess fluid, while peritoneal dialysis is gaining traction due to its home treatment capabilities [21][23] Market Size and Growth - The Chinese blood purification device market size increased from 116.3 billion yuan in 2019 to 145.0 billion yuan in 2023, with a CAGR of 5.7%, and is expected to reach 515.2 billion yuan by 2030, with a projected CAGR of 19.9% from 2023 to 2030 [26] - The market for blood purification devices is segmented into blood purification machines, blood purification consumables, and other related equipment, with significant growth expected across all segments [26] Competitive Landscape - Domestic companies are rapidly catching up to international competitors in the blood purification consumables market, achieving nearly 50% market share in key areas [27] - The report indicates that the domestic market for blood purification machines still has room for growth, as these products have historically relied on imports due to high technical barriers [27][34] - The report emphasizes that domestic manufacturers are improving their technology and performance, positioning themselves to capture a larger market share [29][34]

Group 1 - Vaccination is a crucial safeguard for building a strong public immunity barrier, and health literacy is key to enhancing public health awareness [1][4] - The competition aims to improve the professional skills of healthcare workers in vaccination and health science communication, expanding the outreach of vaccination promotion [1][3] - The event featured various formats such as mandatory questions, quick-response questions, and science exhibition performances to showcase both technical skills and teamwork in health communication [2] Group 2 - The competition serves as a comprehensive assessment of the vaccination team's professional capabilities and an important opportunity for industry exchange and improvement [3] - The health authorities emphasize that the professional ability and science communication skills of the vaccination team are directly related to the strength of public health defenses [3] - The district has established 41 vaccination clinics and aims to enhance the standardization and digitalization of vaccination services, with significant achievements in electronic vaccination certificates and adult immunization prescriptions [3]

今年以来，疏附县积极探索"科技+医疗"深度融合新模式，此次引入的无人机为中国电信出资750万 元援建的重点项目，该机型飞行高度为200米、时速可达120公里，最大航程100公里、载重20公斤，15 分钟即可抵达距离疏附县人民医院31公里外的木什乡，有效破解医疗物资配送"最后一公里"难题。 疏附县人民医院副院长郭建林说："无人机的顺利投入，将解决药品配送慢、应急转运难问题，保 障患者急需的药品、急救物资能快速送达。我们计划联合技术团队建立县、乡、村三级信息对接通道， 探索无人机在医疗巡诊、健康宣教、资料配送等方面的应用，切实打通优质医疗服务下沉的'空中通 道'。" 来源：工人日报 本报讯（记者吴铎思 通讯员肖君）日前，新疆维吾尔自治区喀什地区疏附县举行中型医疗无人机 首飞仪式。当日，一架无人机从起降点缓缓升空，机身在低空平稳悬停并调整姿态后，按照预设航线展 开飞行。现场电子屏上，无人机的飞行轨迹、实时速度等清晰可见，全程实现精准定位。 疏附县辽园镇卫生院党支部书记茹鲜古丽·麦麦提说："以前，我们卫生院在药品配送或标本转运 时，需要专人专车到县医院，来回1小时左右，现在有了无人机，10分钟就能对接上，很方便。" ...